Loading…
Loading…
Odyssey Health (OTCMKTS:ODYY - Get Free Report) and Enovis (NYSE: ENOV - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk. Institutional and Insider Ownership 98.5% of Enovis shares are
Agreement Positions Company for Near-Term Revenue and Commercial Launch LAS VEGAS, April 22, 2026 /PRNewswire/ -- Odyssey Health, Inc. (OTCQB: ODYY), a medical device company focused on life-saving technologies, today announced the closing of a definitive sub-license agreement granting its wholly-owned subsidiary, Odyssey Medical Devices, Inc., exclusive worldwide marketing and distribution rights for BreastCheck™. This transaction positions Odyssey to enter the global breast cancer screening market, estimated at approximately $26 billion, with a differentiated, non-invasive, at-home screening solution.
Odyssey Health, Inc. (OTCMKTS:ODYY - Get Free Report) was the recipient of a significant increase in short interest in January. As of January 30th, there was short interest totaling 63,696 shares, an increase of 15,065.7% from the January 15th total of 420 shares. Based on an average trading volume of 125,484 shares, the short-interest ratio
Service agreement and financing facility supports strategic growth and commercialization initiatives Service agreement and financing facility supports strategic growth and commercialization initiatives
Odyssey Medical Devices, Inc., a subsidiary of Odyssey Health Inc., to acquire exclusive global marketing and distribution rights for the BreastCheck® Odyssey Medical Devices, Inc., a subsidiary of Odyssey Health Inc., to acquire exclusive global marketing and distribution rights for the BreastCheck®
LAS VEGAS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTCQB: ODYY) (the “Company” or “Odyssey”), a technology and asset acquisition company focused on developing unique, life-saving medical products is pleased to provide the following update on the development of its Save A Life (“SAL”) choking rescue device. Odyssey has created a prototype device and now plans to continue the advancement of the product with the ultimate goal of filing a submission to the FDA for the life-saving choking rescue device.
LAS VEGAS, NV / ACCESSWIRE / March 27, 2024 / Odyssey Health, Inc. (OTCQB:ODYY), formerly Odyssey Group International, Inc., (the "Company") a company focused on developing unique, life-enhancing medical products, recently filed its quarterly report for the quarter ended January 31, 2024. The Company reported $13.2 million in net income attributable to stockholders and total stockholder equity of $8.7 million.
LAS VEGAS, NV / ACCESSWIRE / January 2, 2024 / Odyssey Health, Inc. (OTCQB:ODYY) ("Odyssey" or the "Company") today announces the closing of the definitive Asset Purchase Agreement, that was entered into on October 4, 2023, with Oragenics, Inc., (OGEN:NYSE American) under which Oragenics acquired Odyssey's proprietary assets related to its neurological drug therapy platform under dvelopment. The assets include drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as Odyssey's proprietary powder formulation and its nasal delivery device.